CardiacWire

MARCH 24, 2024

Less than two weeks after Novo Nordisk’s weight-loss drug Wegovy gained expanded FDA approval for cardiovascular event risk reduction, CMS issued a new Medicare Part D guidance that allows coverage of obesity drugs for senior patients with “an additional medically accepted indication”… like cardiovascular disease.

Medicare 59

Medicare Obesity CMS Medicaid 59

DAIC

JUNE 4, 2024

I had had a heart attack previously. Navigating Post-Stroke Recovery at Home: One Patient's Experience A ”mildly impaired” stroke patient with atrial fibrillation who was discharged reported, “I knew my local pharmacist, and they knew my prescriptions. I couldn’t dispense my medications into daily doses.

Stroke 115

Stroke Strokes Innovation Research 115

DAIC

MARCH 7, 2024

Patients treated with CardiAMP cell therapy saw an almost 5% lower rate of heart death equivalents at up to two years compared to control patients treated with heart failure medication alone (8.3% The CardiAMP HF II trial is expected to similarly secure CMS reimbursement. vs. 13.2%, respectively).

Heart Failure 105

Heart Failure Biomarkers CMS Reimbursement 105